Page 9 - Technologies Munich News Today

Bruce Power says it’s closer to producing the medical isotope Lutetium-177, used to target cancers such as neuroendocrine tumours and prostate cancers.

The latest nuclear news in Nuclear Power Industry about utilities, companies, suppliers in the nuclear energy market.

Bruce Power announced this week it’s closer to producing the medical isotope Lutetium-177, used to target cancers such as neuroendocrine tumours and prostate…

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the first patient has been treated in its second pivotal phase III clinical trial, COMPOSE

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the study design for its phase III trial, COMPOSE (NCT04919226), at the

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

Investigator-initiated multicenter Phase I study in glioblastoma with CAXII-targeting, 177Lu radiolabeled antibody Fab fragment (LuCaFab) in preparation, led by University of Münster as the sponsor

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster will present a corporate overview and update at the virtual 40th

Grand Pharma has licensed the development, manufacturing and commercialization rights of ITM's Targeted Radionuclide Therapeutic candidates ITM-11 (n.c.a 177Lu-edotreotide) and ITM-41 (n.c.a 177Lu-zoledronate)

Press release content from Business Wire. The AP news staff was not involved in its creation.